We believe in the future of precision medicine
CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, NASH, NAFLD/NASH, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once-a-week, subcutaneous injection. One molecule with multiple opportunities.
Welcome to the future of target specific, precision medicine. Welcome to CytoDyn.
We are a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Our lead candidate leronlimab (PRO 140) belongs to a new class of therapeutics called viral-entry inhibitors and is an experimental monoclonal antibody for HIV treatment.